12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Trimesta: Completed Phase II enrollment

Synthetic Biologics (formerly Adeona Pharmaceuticals Inc.) completed enrollment of 164 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 8 mg Trimesta daily plus Copaxone glatimer...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >